Methods of efficiently reducing intraocular pressure
US11850249B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 5, 2021 |
| Grant date | Dec 26, 2023 |
| Priority date | — |
| Expiry date | Oct 5, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are pharmacologically acceptable and ophthalmologically suitable compositions and methods of their use in treating ophthalmic diseases or related conditions. In aspects, the invention provides compositions comprising effective amounts of carbonic anhydrase inhibitor(s) and alpha-2-adrenergic agonist(s). In facets, compositions comprise a penetration enhancer component comprising one or more penetration enhancer compound(s)/molecule(s). In aspects, the invention provides compositions comprising effective amounts of brimonidine compound(s) and brinzolamide compound(s) capable of being administered once or twice daily for the treatment of elevated intraocular pressure, but which provide similar efficacy to a similar or substantially identical reference product requiring administration three times per day. In facets, the invention provides compositions capable of being administered at a frequency resulting in providing a lower total dose of both brinzolamide and brimonidine compound(s) to a recipient, but nonetheless are as or more effective in IOP control as such similar or substantially identical reference products.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.